2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)

Wednesday | Oct 7th, 2015 | Congress Center (Hörsaal 1 – 3)  
Marien Hospital Herne

Accreditation by the Medical Chamber of Westfalia-Lippe has been applied for and is pending.
Dear colleagues,

Peritoneal metastasis is a significant unmet medical need. Peritoneal metastasis develop in several types of common cancers: ovarian, gastric, colorectal, appendiceal, hepatobiliary and pancreatic. Peritoneal metastasis is frequent with 20’000 new cases/year in Germany and develops in up to 75% with ovarian cancer and 55% of patients with gastric cancer. Peritoneal metastasis has a dismal prognosis: one-year survival is less than 10-25 percent. Almost all patients with peritoneal metastasis either relapse or die.

The interdisciplinary therapy center for peritoneal cancer at the Ruhr-University Bochum, Marien Hospital Herne, is proposing research-driven care for patients with peritoneal and pleural metastasis. Our center has evaluated over the last 3 years around 2500 patients with peritoneal surface malignancies and belongs to the most active specialized centers in Germany and in Europe. A wide range of therapeutic options is available for patients with peritoneal metastasis: conventional systemic chemotherapy, biologicals, immunotherapy, cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC), intraperitoneal chemotherapy, palliative surgery, endoscopic procedures, ascites control, nutritional therapy, etc. All these therapies are available at our center. In addition, we are investigating Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) as a novel therapeutic approach.

PIPAC relies on logical physical principles: local administration into the body cavity to improve therapeutic ratio, gaseous form to achieve homogeneous drug distribution, pressure application to enhance convective drug uptake into tumor nodes, and minimally-
invasive approach to minimize operative trauma. Only approved drugs are applied, with
proven efficacy in the cancer types concerned. PIPAC allows repeated therapy cycles and
objective tumor response assessment.

This rationale has been confirmed in preclinical and clinical studies. In a recent Phase-2
regulatory trial in peritoneal metastasis of recurrent, platin-resistant ovarian cancer, PI-
PAC was able to induce 62% response according to RECIST criteria, or 80% regression in
blinded histology. These results appear encouraging in the salvage situation. Comparable
results have been obtained in retrospective series in gastric and colorectal cancer, as
well as in malignant mesothelioma. In individual cases, complete radiological and histo-
logical responses have been induced. All together, we can now report on more than 900
PIPAC cases and on their evolution.

We would like to invite you to our second symposium on PIPAC on October 7th, 2015.
In the morning session, you will be provided with an update on the latest research and
treatment results. In an attractive session, we will discuss the pros and cons of the sys-
temic palliative chemotherapy as an effective treatment for peritoneal metastasis. In the
afternoon we will focus our efforts on the definition of a research agenda together with
the international PIPAC community.

We have already trained 50+ cancer centers worldwide in PIPAC technology. Our hope
is that through the symposium the German and international research community will
continue to grow and speed up generation of high-level scientific evidence.

We are looking forward meeting you in Herne.

Marc A. Reymond, Clemens Tempfer, Jürgen Zieren and Dirk Strumberg
09.00  Introduction
Marc A. Reymond

09.15  What is new with PIPAC? Short presentations
Chair: Martin Mörtensen

PIPAC in Herne: retrospective analysis after 900 cases
Marc A. Reymond

Phase-2 PIPAC-GA1 trial: intermediate analysis
Urs Giger-Pabst

Phase-1 PIPAC-OV2 dose escalation study
Clemens Tempfer

Quality of life
Katharina Odendahl

Nutritional aspects
Katharina Nordhausen

Molecular markers of tumor response in ovarian cancer
Günther A. Rezniczek

Pharmacology of HIPEC vs. PIPAC with oxaliplatin
Marc Pocard

Electrostatic precipitation PIPAC (ePIPAC)
Tinatin Kakchekeeva

Histological tumor response assessment
Wiebke Solass

10.45  Coffee break
Debate: Systemic palliative chemotherapy is effective for treating peritoneal metastasis
Moderator: Wim Ceelen
Pro: Sandrine Faivre
Contra: Jörg Pelz
Discussion

Lunch break

Workshop: coordinating research; setting up study protocols and funding
How to implement a PIPAC program within 3 months
Martin Hübner
Introducing the PIPAC-PITAC Registry
Cedric Demtröder

Gastrointestinal group
- Gastric cancer: neoadjuvant PIPAC
- Colorectal cancer: a dose-escalation study
- Pseudomyxoma peritonei (PMP)
- Mesothelioma
- ePIPAC in gallbladder cancer
- ePIPAC in pancreatic cancer

Gynaecological group
- Ovarian cancer: a prospective randomized trial (PIPAC-OV3)
- ePIPAC in ovarian cancer
- ancillary biological studies

Plenum
15.15 Research roadmap of the gastrointestinal group
15.30 Research roadmap of the gynaecological group
15.45 Conclusion
16.00 End of the meeting
Speakers and Chairmen

Prof. Wim Ceelen | MD PhD
Head, Department of Gastrointestinal Surgery and Surgical research, University Hospital, Ghent, Belgium

Cedric Demtröder | MD
Consultant surgeon, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany

Prof. Sandrine Faivre | MD PhD
Vice Chairman, Dept. of Onco-hematology, University of Lausanne, Switzerland

Tinatin Kakchekeeva | MD
Resident, Helios Klinikum Stralsund, Germany

Urs Giger-Pabst | MD
Consultant surgeon, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany

Martin Hübner | MD
Associate Professor of Surgery, University of Lausanne, Switzerland

Prof. Martin Mörtensen | MD PhD
Head of Upper GI Section and Head of Surgical Research, Dept. of Surgery, University of Ödense, Denmark

Katharina Nordhausen | MS
Dept. of Surgery, Ruhr-University Bochum, Germany
Katharina Odendahl | MS
Dept. of Surgery, Ruhr-University Bochum, Germany

Prof. Jörg Pelz | MD
Vice Chairman, Dept. of Surgery, University of Würzburg, Germany

Prof. Marc Pocard | MD PhD
Professor and Head, Gastrointestinal surgery, Hôpital Lariboisière, Paris 7 University, Paris, France

Günther A. Rezniczek | PhD
Head, Research Unit, Dept. of Gynecology and Obstetrics, Ruhr-University Bochum, Germany

Prof. Marc Reymond | MD MBA
Head, Surgical oncology and Therapy Center for Peritoneal Cancer, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany

Wiebke Solass | MD
Resident, Institute of Pathology, Medical School Hanover, Germany

Prof. Clemens Tempfer | MD MBA
Chair and Head, Department of Gynaecology and Obstetrics, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany
Symposium Venue
Congress Center (Hörsaal 1 – 3)
Marien Hospital Herne
Universitätsklinikum der Ruhr-Universität Bochum
Hölkeskampring 40
44625 Herne

Congress Management
Mrs. Silke Schnarre and Mrs. Stefanie Feiertag I Klinik für Chirurgie
Marien Hospital Herne I Hölkeskampring 40 I 44625 Herne
Phone +49 23 23 - 499 - 14 78 | Fax +49 23 23 - 499 - 33 92
bauchfell@marienhospital-herne.de

Information and registration
www.marienhospital-herne.de / PIPAC-Symposium

Participation to the symposium is free.